Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance
NCT01156298 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 383
Last updated 2012-08-03
Summary
Phase IV, multi-center, non-treatment, observational, registry study to determine long term effects of AVONEX® therapy on EDSS, MRI, QoL, and cognition.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-06-30
- Primary Completion
- 2016-12-31
- Completion
- 2017-03-31
Countries
- United States
Study Locations
More Related Trials
-
Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis
NCT00037102 ·Status: COMPLETED ·Phase: PHASE4
-
Avonex PEN Satisfaction and Patients Experience Clinical Trial
NCT01366040 ·Status: COMPLETED
-
A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
NCT00217295 ·Status: UNKNOWN ·Phase: PHASE2
-
Immunogenicity and Safety Study of Serum-Free Avonex
NCT00912860 ·Status: COMPLETED ·Phase: PHASE2
-
AVONEX® Combination Trial - "ACT"
NCT00112034 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
NCT00030966 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Safety Extension Study of Avonex
NCT00915460 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS
NCT00463710 ·Status: COMPLETED
-
Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
NCT00168766 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
NCT00913666 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
NCT00599274 ·Status: COMPLETED
-
Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
NCT01272128 ·Status: COMPLETED
-
Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)
NCT01181115 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
NCT00828204 ·Status: COMPLETED ·Phase: PHASE3
-
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
NCT00037115 ·Status: WITHDRAWN ·Phase: PHASE4
-
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
NCT00179478 ·Status: COMPLETED ·Phase: PHASE4
-
Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS
NCT00232193 ·Status: COMPLETED
-
Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)
NCT00986960 ·Status: WITHDRAWN ·Phase: PHASE2
-
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
NCT00784836 ·Status: TERMINATED ·Phase: PHASE3
-
Canadian Avonex PEN Productivity Study
NCT01489748 ·Status: COMPLETED
-
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
NCT01864148 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT01975298 ·Status: WITHDRAWN ·Phase: PHASE3
-
Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
NCT00493077 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
NCT00324506 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
NCT04032158 ·Status: TERMINATED ·Phase: PHASE3